The Consolidated Appropriations Act of 2023 (Omnibus) amended the Federal Food, Drug, and Cosmetic Act to require medical device manufacturers to address cybersecurity. As of March 29, 2023, they must provide cybersecurity details in premarket submissions. The Omnibus mandates plans for postmarket cybersecurity vulnerabilities, device cybersecurity demonstrations, and software bill of materials (SBOM) disclosures. Starting October 1, 2023, the FDA will reject submissions not meeting cybersecurity criteria, emphasizing proactive cybersecurity measures.

Even More Schedule 1 Mods Found to Contain Malware
The Schedule 1 modding community is facing a potential threat as more modifications have been discovered containing dangerous malware. Mods including “Just Enough Drugs” and